China Enterprise Confederation and China Enterprise Directors Association (CEC&CEDA) recently released its China Top 500 List for 2015. Huadong Medicine Co., Ltd. (“Huadong Medicine”), a core subsidiary of China Grand Enterprises’ Pharmaceuticals & Healthcare, is ranked the 478th with its robust growth in revenue and the 258th in manufacturing. It is one of the only ten pharmaceutical companies made to China Top 500 Manufactures List in 2015.

As the key representative of CGE’ Pharmaceutical and Healthcare sector, Huadong Medicine is a listed major pharmaceutical company with integrated R&D, manufacturing, distribution and logistics. It mainly engages in the manufacture and sales of immunosuppressive drugs, TCM, synthetic pharmaceuticals and genetically engineered drugs, and in wholesale and distribution of Western medicine and TCM, Chinese medicinal herbs and medical devices. It also undertakes state, provincial and city level government special drug reserve tasks.

In recent years, faced with opportunities and challenges, Huadong Medicine has been speeding up innovation and transformation of its production, sales and marketing, R&D capabilities, and management processes as well as profit models by leveraging its advantages in scale, product portfolio, brand proposition and marketing capabilities to drive solid and sustainable growth. 

Attachment: Huadong Medicine is ranked 268th on the Fortune China 500 list for 2015.